Financial reports
10-K
2023 FY
Annual report
13 Feb 24
10-Q
2023 Q3
Quarterly report
26 Oct 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
ARS
2022 FY
Annual report to shareholders
23 Mar 23
10-K
2022 FY
Annual report
14 Feb 23
10-Q
2022 Q3
Quarterly report
26 Oct 22
10-Q
2022 Q2
Quarterly report
27 Jul 22
10-Q
2022 Q1
Quarterly report
29 Apr 22
10-K
2021 FY
Annual report
9 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
18 Mar 24
8-K
Strengthening Neuroscience Portfolio
18 Mar 24
8-K
Other Events
22 Feb 24
8-K
Departure of Directors or Certain Officers
15 Feb 24
8-K
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
14 Feb 24
8-K
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
2 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
22 Dec 23
8-K
Other Events
13 Nov 23
8-K/A
Departure of Directors or Certain Officers
31 Oct 23
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
16 Feb 24
FWP
Free writing prospectus
14 Feb 24
424B2
Prospectus for primary offering
13 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
12 Feb 24
SC TO-T
Third party tender offer statement
25 Jan 24
SC TO-C
Information about tender offer
26 Dec 23
424B5
Prospectus supplement for primary offering
1 Nov 23
FWP
Free writing prospectus
30 Oct 23
Proxies
PRE 14A
Preliminary proxy
18 Mar 24
DFAN14A
Additional proxy materials by non-management
22 Dec 23
DFAN14A
Additional proxy materials by non-management
22 Dec 23
DFAN14A
Additional proxy materials by non-management
10 Oct 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEFA14A
Additional proxy soliciting materials
10 Apr 23
DEFA14A
Additional proxy soliciting materials
23 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
DEFA14A
Additional proxy soliciting materials
20 Apr 22
PX14A6G
Letter to shareholders
5 Apr 22
Other
UPLOAD
Letter from SEC
8 Apr 22
CORRESP
Correspondence with SEC
6 Apr 22
CORRESP
Correspondence with SEC
18 Jan 22
UPLOAD
Letter from SEC
16 Dec 21
UPLOAD
Letter from SEC
1 Feb 21
CORRESP
Correspondence with SEC
6 Jan 21
UPLOAD
Letter from SEC
22 Dec 20
EFFECT
Notice of effectiveness
16 Jun 20
CORRESP
Correspondence with SEC
10 Jun 20
CORRESP
Correspondence with SEC
10 Jun 20